Alprazolam increases food intake in humans

The present study investigated the effect of alprazolam on the pattern of food intake in seven male participants living in a residential laboratory for 17 days. A wide selection of meals, snacks and beverages was freely available. Capsule administration occurred at 1300 and 1730 hours. Food intake on days when alprazolam (0.75 mg) was administered (days 2, 11) was compared to days when no capsule (days 1, 9) or placebo (days 3, 10) was administered. Alprazolam increased total caloric intake by approximately 975 kcal from a baseline of 2800 kcal. Alprazolam increased the number of eating occasions occurring in the evening (1700–2330 hour), without altering the size of eating occasions (kcal), or the proportion of total calories derived from carbohydrate, fat and protein. These data demonstrate alprazolam’s robust effects on food intake in humans. Received: 18 February 1997 /Final version: 13 April 1997     

帕罗西汀与阿普唑仑治疗广泛性焦虑症的对照研究

目的 比较帕罗西汀与阿普唑仑治疗广泛性焦虑症的疗效及安全性。方法 将92例广泛性焦虑症随机分配至帕罗西汀组及阿普唑仑组各46例。帕罗西汀治疗剂量为20mg／d，阿普唑仑为1.2-2．4mg／d，观察时间均为4周。疗效评定采用HAMA及SAS，安全性评价应用TESS和实验室检查及体查。结果 经过治疗4周后，帕罗西汀组显效率为71.7％、有效率为93．5％，与阿普唑仑组的69．6％及95．7％相当。帕罗西汀常见不良反应为恶心、头痛、口干、出汗、厌食及便秘等，且均较轻微，患者依从性好。结论 帕罗西汀是一种安全而有效的抗焦虑药，耐受性及依从性均好。     

一舒与佳乐定对广泛性焦虑的疗效观察

目的 :比较一舒与佳乐定对广泛性焦虑的疗效。方法 :将 62例广泛性焦虑患者随机均分为两组 ,分别给予一舒和佳乐定治疗 ,疗程 8周 ,用HAMA、TESS评定疗效与副反应。结果 :疗程结束时 ,一舒组HAMA评分由入组时的 2 6 58± 4 72降为 9 1 6± 5 2 8,佳乐定组HAMA评分由 2 5 36± 7 85降为 1 3 1 9± 6 51 ,两组有显著差异 (P <0 0 5) ;一舒组TESS评分低于佳乐定组 (P <0 0 5)。结论 :一舒与佳乐定治疗广泛性焦虑都有效 ,但一舒疗效较好 ,副反应轻微     

文拉法辛治疗广泛性焦虑症对照研究

目的：比较文拉法辛与阿普唑仑治疗广泛性焦虑症的疗效及不良反应。方法：对66例广泛性焦虑症随机分为两组，分别服用文拉法辛或阿普唑仑。疗程6周。于治疗前及治疗后第2、4、6周末进行汉密尔顿焦虑量表(HAMA)及副反应量表(TESS)评定疗效和不良反应。结果：文拉法辛与阿普唑仑的疗效相仿，文拉法辛不良反应少而轻，无成瘾性。结论：文拉法辛是治疗广泛性焦虑症的安全、有效药物。     

Lack of multiple dosing effect of sertindole on the pharmacokinetics of alprazolam in healthy volunteers

 The effect of sertindole (a new selective antipsychotic compound) on the pharmacokinetic disposition of alprazolam was investigated. Fourteen subjects who completed the study received a single 1 mg dose of alprazolam without or with concomitant sertindole 12 mg daily. Coadministration of sertindole and alprazolam led to a half-hour decrease (P < 0.05) in mean T_max value (alone: 1.2 h, in combination: 0.7 h) and a 1.6-h increase in the mean t_1/2value (12.5 ± 3.2 versus 14.3 ± 3.4 h, P < 0.05) of alprazolam. The mean C_max (18.5 ± 4.9 versus 18.5 ± 4.8 ng/ml) and AUC (266 ± 68 versus 275 ± 57 ng⋅h/ml) values of alprazolam did not change statistically significantly in the presence of sertindole (P > 0.05). These pharmacokinetic changes are minor and not considered to be of clinical significance. Although both sertindole and alprazolam are substrate for CYP3A4 (cytochrome P-450 3A4), the results in this study suggest that sertindole is not an inhibitor of the metabolism of alprazolam. Received: 5 March 1997/Final version: 28 July 1997     

Subtyping panic disorder by major depression and avoidance behaviour and the response to active treatment

Summary In order to establish the clinical validity of currently used ways of subtyping panic disorder the predictive power of associated current avoidance behaviour and (secondary) major depression for the response to active treatment (alprazolam, imipramine) was tested. The analysis was based on the data from the Cross-National-Collaborative-Panic-Study. Limited support for validity evidenced by predicting drug response was found for grading panic disorder by the severity of avoidance behaviour: patients with panic attacks and agoraphobia are more responsive to imipramine (compared with alprazolam) when using the reduction of the total number of panic attacks (or of spontaneous panic attacks) as the outcome criterion; patients without any avoidance behaviour did better with alprazolam (compared with imipramine).     

Alprazolam in the treatment of generalized anxiety and panic disorders: A double-blind placebo-controlled study

In a double-blind controlled study lasting 8 weeks, 50 anxious psychoneurotic outpatients with a primary diagnosis of generalized anxiety or panic disorder were randomly assigned to alprazolam (n=30), a new benzodiazepine, or placebo (n=20), after a washout period of 1 week. Alprazolam at dosages between 0.25 and 3 mg/day was found to be significantly better than placebo in the treatment of either disorder. The finding that alprazolam was effective in the treatment of panic disorder is of interest as this diagnostic category is usually treated with tricyclic antidepressants or MAO inhibitors.     

针刺对失眠症患者的疗效

〔摘 要〕 目的：研究针刺对失眠症患者的疗效及炎症因子水平影响。方法：选取广州新海医院 2016 年 5 月至 2019 年 3 月 期间收治的 114 例失眠症患者,随机分观察组（针刺治疗）与对照组（阿普唑仑片治疗）,各 57 例。比较两组患者睡眠 质量、炎症因子水平、总有效率与不良反应。结果：经治疗观察组患者的睡眠时间、入睡时间、日间功能障碍、睡眠障碍 与睡眠效率的评分低于对照组,差异具有统计学意义（P ＜ 0.05）;治疗前两组患者的白细胞介素 – 6 与肿瘤坏死因子 –α 水平比较,差异无统计学意义（P ＞ 0.05）;治疗后观察组白细胞介素 – 6 与肿瘤坏死因子 – α 水平较对照组低,差异具有 统计学意义（P ＜ 0.05）;观察组患者治疗总有效率为 98.24 %,高于对照组的 87.71 %,差异具有统计学意义（P ＜ 0.05）; 观察组患者不良反应发生率为 5.26 %,低于对照组的 17.54 %,差异具有统计学意义（P ＜ 0.05）。结论：对失眠症患者采 用针刺治疗能改善睡眠质量,降低炎症因子水平,提高疗效且避免不良反应发生。     

丁螺环酮治疗广泛性焦虑对照研究

目的:比较丁螺环酮与阿普唑仑治疗广泛性焦虑的临床疗效及不良反应。方法:采用随机分组的方法,将78例广泛性焦虑随机分为丁螺环酮组(39例)和阿普唑仑组(39例),疗程6周。用焦虑自评量表(SAS)、Hamilton焦虑量表(HAMA)和治疗中出现的症状量表(TESS)评定疗效和不良反应。结果:丁螺环酮与阿普唑仑疗效相当,不良反应较阿普唑仑少而轻。结论:丁螺环酮治疗广泛性焦虑安全、有效,且不良反应轻微。     

紫石百合汤治疗60例老年人失眠的临床观察

目的：探讨紫石百合汤治疗老年人失眠的临床疗效。方法：将2012年12月-2013年5月期间门诊收治的60例失眠患者随机分成两组,观察组35例,给予紫石百合汤,对照组25例给予阿普唑仑。结果：观察组的总有效率（94.3%%）显著高于对照组（72.0%）,具有统计学意义（P〈0.05）。两组治疗后PSQI各项评分均较治疗前有明显改善,差异具有统计学意义（P〈0.05）;但观察组在改善睡眠时间、睡眠效率、睡眠质量上优于对照组,差异具有统计学意义（P〈0.05）。治疗后两组在SAS评分和SDS评分方面均较治疗有明显改善,差异具有统计学意义（P〈0.05）;两组间治疗后对比有明显差异（P〈0.05）。两组不良反应比较具有显著差异,具有统计学意义（P〈0.05）。结论：紫石百合汤治疗老年人失眠的临床疗效确切,且无毒副作用,值得临床推广应用。